Phase 2 Study of AMG 193 for Patients with Advanced Non-Small Cell Lung Cancer with MTAP Deletion
Sponsor: Amgen
ClinicalTrials ID:NCT06593522
This study is testing the safety and effectiveness of two different doses of the drug AMG 193 in patients with advanced non-small cell lung cancer (NSCLC) that has a specific genetic deletion called MTAP. The study will also evaluate how well the drug works through an independent review.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to determine if the drug AMG 193 is safe and effective for treating patients with advanced non-small cell lung cancer (NSCLC) that has a specific genetic deletion known as MTAP. Researchers will test two different doses of AMG 193 and assess its effectiveness through an independent review process.
Eligibility Criteria
Inclusion Criteria
- Have advanced non-small cell lung cancer (NSCLC) with a specific genetic deletion called MTAP.
- Have already received at least one treatment for advanced cancer that did not work or the cancer came back.
- Provide a previous tissue sample for analysis.
- Have a life expectancy of more than 3 months, as determined by the study doctor.
- If you have brain metastases, they must have been treated with radiation or surgery at least 14 days before starting the study.
- If you have untreated brain metastases, they must be small (2 cm or less) and not causing symptoms or requiring steroid treatment.
Exclusion Criteria
- Have tumors with certain genetic mutations that can be treated with specific targeted therapies.
- Have had major surgery within 28 days before starting the study.
- Have untreated brain metastases that are causing symptoms or are larger than 2 cm.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| City of Hope National Medical Center | 91010 | Duarte | California |
| City of Hope Orange County Lennar Foundation Cancer Center | 91010 | Duarte | California |
| Valkyrie Clinical Trials | 90067 | Los Angeles | California |
| University of California Los Angeles | 90095 | Los Angeles | California |
| Eastern Connecticut Hematology and Oncology Associates | 06360 | Norwich | Connecticut |
| Medstar Georgetown University Hospital | 20007 | Washington | District of Columbia |
| Our Lady of the Lake Cancer Institute | 70808 | Baton Rouge | Louisiana |
| Trinity Health Saint Joseph Mercy Ann Arbor | 48106 | Ann Arbor | Michigan |
| Cancer and Hematology Centers of Western Michigan | 49503 | Grand Rapids | Michigan |
| Sarah Cannon Research Institute Oncology Partners | 37203 | Nashville | Tennessee |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.